Lund, Sweden, June 23, 2020 - Xintela today announces that the European Patent Office (EPO) has issued a preliminary approval ("Intention to grant") for the company's patent application related to antibody treatment of Glioblastoma and other tumors of the brain using the company's target molecule integrin α10β1.
Xintela's patent application (publication number EP3258964) covers the use of integrin α10β1 antibodies for treatment and diagnosis of tumors of the central nervous system (CNS). The present intention to grant is followed by an administrative process leading to the grant of the patent. The patent, which broadens and extends Xintela's fundamental protection in this field, will be valid until 2036.
“We are very pleased with this intention to grant communication which constitutes a validation of the strength and breadth of the company’s oncology project, and adds significant value to our oncology business,” says Xintela's CEO Evy Lundgren-Åkerlund.
Xintela has previously reported that the company's targeting ADC (Antibody-Drug Conjugate) antibodies have demonstrated killing effects on glioblastoma cells both in cell studies and in an animal model. The results have been published in the journal Cancers (2019, Vol. 11, pg 587). Additionally, in December 2019, Xintela announced that the company's function-blocking antibodies have demonstrated an inhibitory effect on glioblastoma tumors in a preclinical study. The current patent application also protects the target molecule integrin α10β1 and thereto targeting antibodies for treatment of other cancers of the CNS.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 23rd of June 2020.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
CEO Evy Lundgren-Åkerlund presents the company at ProHearings Capital Market Day in Stockholm on June 1, 2023.
Watch the video interview with CEO Evy Lundgren-Åkerlund (in Swedish).
